Abstract 2045P
Background
The success of cancer therapy relies on patient adherence, which refers to the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider ( WHO 2003 ). Several PROMs were developed to measure patient adherence to (cancer) therapy. In light of this, our study aims to offer a comprehensive overview of PROMs in the cancer field, with a specific focus on the adherence dimensions captured.
Methods
A systematic review of systematic reviews was performed to identify studies of cancer patients that apply PROMs to measure adherence without restriction to the type of therapy. Databases of Pubmed and Embase were searched up to March 2022 and studies were selected based on predefined eligibility criteria. A qualitative synthesis was used determining measurement of adherence and dimensions of PROMs according to the WHO definition for adherence.
Results
After screening 4483 results a total of 56 literature reviews were included capturing 1064 studies that focused on cancer patients. Out of the 56 literature reviews included in our final analysis, the majority (45) focused on medication adherence, while 18 studies assessed adherence to dietary recommendations, and 13 studies examined adherence to lifestyle changes. Three studies investigated other dimensions of adherence. Data collection was primarily carried out via questionnaires and most studies applied self-developed, non-validated PROMs. PROMs mainly measured one dimension of adherence, even though the content of items were overlapping between medication, diet and lifestyle.
Conclusions
This systematic literature review provides a comprehensive overview of PROMs used to assess adherence in oncology. Our analysis highlights the predominance of studies measuring medication adherence and underscores the need for greater attention to other dimensions of adherence. Our findings can inform the choice of PROMs to monitor patients’ adherence in clinical practice and enhance health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06